<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04278638</url>
  </required_header>
  <id_info>
    <org_study_id>2019008</org_study_id>
    <nct_id>NCT04278638</nct_id>
  </id_info>
  <brief_title>IORT in Local Advanced Laryngocarcinoma</brief_title>
  <acronym>ILAL</acronym>
  <official_title>Study of Safety and Feasibility With or Without Intraoperative Radiation in Local Advanced Laryngocarcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tianjin First Central Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tianjin First Central Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The incidence of laryngeal cancer accounts for about 1 ~ 5% of the total body tumors. For the
      surgical treatment of laryngeal cancer, the development trend of laryngocarcinoma treatment
      is to improve the local control rate, preserve the laryngeal function of patients as far as
      possible, and improve the life quality of patients. The efficacy, safety and feasibility of
      intraoperative radiotherapy (IORT) in head and neck cancer has been demonstrated in multiple
      institutional (3-5) studies to optimize local control. It is still unclear whether IORT can
      improve the local control and have efficacy, safety and feasibility in clinic. The purpose of
      this study was to observe the efficacy, safety and feasibility of IORT in local advanced
      laryngocarcinoma .
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 1, 2018</start_date>
  <completion_date type="Anticipated">December 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">July 1, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>2-year disease free survival</measure>
    <time_frame>2 years</time_frame>
    <description>Compare 2-year disease free survival in patients with local advanced laryngocarcinoma treated with or without IORT.
Criteria for disease free survival means MRI and laryngoscopy (PET-CT if possible) indicate tumor free.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>local recurrence rate</measure>
    <time_frame>1 year</time_frame>
    <description>In this study, no matter whether distant metastases occurred, if there was the presence of any anastomotic or lateral node recurrences, it was definded as local recurrence.
Criteria for local recurrence include (1) MRI results suggestes local tumor recurrence, (2)Laryngoscopy indicates local tumor recurrence.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>tissue necrosis</measure>
    <time_frame>2 years</time_frame>
    <description>Compare the risk of tissue necrosis as determined visually by the Laryngoscope at 2 years after treatment in patients with local advanced laryngocarcinoma treated with or without IORT.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>time of wound healing</measure>
    <time_frame>up to 1 month</time_frame>
    <description>Compare the time of wound healing after surgery in patients with local advanced laryngocarcinoma treated with or without IORT.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>fibrosis</measure>
    <time_frame>2 years</time_frame>
    <description>Compare the risk of fibrosis as determined visually by the Laryngoscope at 2 years after treatment in patients with local advanced laryngocarcinoma treated with or without IORT.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>pharyngeal fistula</measure>
    <time_frame>3 months</time_frame>
    <description>Pharyngeal fistula means that saliva is stored in subcutaneous or subincisional tissues, resulting in abscess cavity rupture to the skin or incision margin, making the hypopharyngeal and esophageal lumen communicate with the skin to form a sinus tract, through which saliva or food can spill out to the skin, forming a skin fistula.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Laryngeal Neoplasms</condition>
  <arm_group>
    <arm_group_label>with IORT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>without IORT</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>IORT</intervention_name>
    <description>IORT in surgery of laryngocarcinoma</description>
    <arm_group_label>with IORT</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>surgery</intervention_name>
    <description>total laryngectomy or hemilaryngectomy</description>
    <arm_group_label>with IORT</arm_group_label>
    <arm_group_label>without IORT</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>External radiotherapy</intervention_name>
    <description>External radiotherapy</description>
    <arm_group_label>with IORT</arm_group_label>
    <arm_group_label>without IORT</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. adults over the age of 18;

          2. radiographic or pathological diagnosis of local advanced laryngocarcinoma (according
             to NCCN guidelines);

          3. the expected survival time â‰¥ 3 months;

          4. sign informed consent for treatment and research with self-knowledge.

        Exclusion Criteria:

          1. there is distant metastasis;

          2. pregnant women;

          3. patients with CT/MRI contraindications;

          4. the patient fails to receive treatment and/or follow-up as scheduled;

          5. bad fluid and organ function decompensation;

          6. multiple primary cancers;

          7. patients participating in other trials.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Xinyuan Gong</last_name>
    <phone>+8613436640313</phone>
    <email>gxy0007@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Tianjin First Central Hospital</name>
      <address>
        <city>Tianjin</city>
        <state>Tianjin</state>
        <zip>300000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xinyuan Gong</last_name>
      <phone>+8613436640313</phone>
      <email>gxy0007@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>January 16, 2020</study_first_submitted>
  <study_first_submitted_qc>February 18, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 20, 2020</study_first_posted>
  <last_update_submitted>February 18, 2020</last_update_submitted>
  <last_update_submitted_qc>February 18, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 20, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Tianjin First Central Hospital</investigator_affiliation>
    <investigator_full_name>LiLi</investigator_full_name>
    <investigator_title>director of head and neck surgery division</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Laryngeal Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

